Vincent Aurentz
CIK: 0001657494
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Feb 21, 2026IKT
Inhibikase Therapeutics, Inc.
Disposition(D)Direct255.3K shares- - Jun 30, 2025IKT
Inhibikase Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
108.2K shares- - Feb 21, 2025IKT
Inhibikase Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
134.4K shares- - Feb 21, 2025IKT
Inhibikase Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
134.4K shares- - Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
Disposition(D)DirectEmployee Stock Option (right to buy)
12.4K shares- - Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
Disposition(D)DirectEmployee Stock Option (right to buy)
12.4K shares- - Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
Disposition(D)DirectEmployee Stock Option (right to buy)
22.5K shares- - Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
Disposition(D)DirectEmployee Stock Option (right to buy)
12.5K shares- - Dec 2, 2024LBPH
Longboard Pharmaceuticals, Inc.
Disposition(D)DirectEmployee Stock Option (right to buy)
7.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 21, 2026 |  IKT Inhibikase Therapeutics, Inc. | Disposition(D) | 255,299 | - | $0 | Direct |
| Jun 30, 2025 | IKT Inhibikase Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 108,176 | - | - | Direct |
| Feb 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 134,427 | - | - | Direct |
| Feb 21, 2025 | IKT Inhibikase Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 134,427 | - | - | Direct |
| Dec 2, 2024 |  LBPH Longboard Pharmaceuticals, Inc. | Disposition(D) Employee Stock Option (right to buy) | 12,367 | - | - | Direct |
| Dec 2, 2024 | LBPH Longboard Pharmaceuticals, Inc. | Disposition(D) Employee Stock Option (right to buy) | 12,367 | - | - | Direct |
| Dec 2, 2024 | LBPH Longboard Pharmaceuticals, Inc. | Disposition(D) Employee Stock Option (right to buy) | 22,500 | - | - | Direct |
| Dec 2, 2024 | LBPH Longboard Pharmaceuticals, Inc. | Disposition(D) Employee Stock Option (right to buy) | 12,500 | - | - | Direct |
| Dec 2, 2024 | LBPH Longboard Pharmaceuticals, Inc. | Disposition(D) Employee Stock Option (right to buy) | 7,214 | - | - | Direct |
1-9 of 9 transactions
About Aurentz Vincent
Aurentz Vincent (SEC CIK 0001657494) files insider reports with the SEC as Director of Inhibikase Therapeutics, Inc. (IKT) and Director of Longboard Pharmaceuticals, Inc. (LBPH).
Signal8 holds 7 ownership filings by Aurentz Vincent (2 Form 3, 5 Form 4), filed between Dec 2, 2024 and Feb 24, 2026. Those filings report 9 transactions, from Dec 2, 2024 to Feb 21, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Aurentz Vincent's filings is in WILMINGTON, DE.
Recent filings by Aurentz Vincent
- Feb 21, 2026: Disposition to issuer transaction of IKT shares (Form 4, code D).
- Jun 30, 2025: Grant or award of IKT derivative securities (Form 4, code A).
- Feb 21, 2025: Grants or awards of IKT derivative securities (2 lines, Form 4, code A).
- Dec 2, 2024: Disposition to issuer transactions of LBPH derivative securities (5 lines, Form 4, code D).
Other insiders filing for Inhibikase Therapeutics, Inc. (IKT)
- Wasserman Scott M., Director
- RA CAPITAL MANAGEMENT, L.P., 10% Owner
- Cabell Christopher, President & Head of R&D
- Munshi Amit, Director
- Iwicki Mark T, Chief Executive Officer
- McIntyre David, Chief Financial Officer